EBS 📈 Emergent Biosolutions - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29089Q1058
EBS: Vaccines, Treatments, Antibodies, Antidotes, Injections, Sprays
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Web URL: https://www.emergentbiosolutions.com
Additional Sources for EBS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EBS Stock Overview
Market Cap in USD | 540m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2006-11-15 |
EBS Stock Ratings
Growth 5y | -66.8% |
Fundamental | -26.4% |
Dividend | 0.30% |
Rel. Strength Industry | 58579 |
Analysts | 3.5/5 |
Fair Price Momentum | 7.71 USD |
Fair Price DCF | 65.94 USD |
EBS Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 1.0% |
EBS Growth Ratios
Growth Correlation 3m | -27.1% |
Growth Correlation 12m | 82.4% |
Growth Correlation 5y | -90.3% |
CAGR 5y | -29.29% |
CAGR/Mean DD 5y | -0.44 |
Sharpe Ratio 12m | 1.54 |
Alpha | 271.54 |
Beta | 1.31 |
Volatility | 69.06% |
Current Volume | 2042.4k |
Average Volume 20d | 1081.5k |
What is the price of EBS stocks?
As of January 01, 2025, the stock is trading at USD 9.56 with a total of 2,042,362 shares traded.
Over the past week, the price has changed by +15.18%, over one month by -2.85%, over three months by +14.49% and over the past year by +269.11%.
As of January 01, 2025, the stock is trading at USD 9.56 with a total of 2,042,362 shares traded.
Over the past week, the price has changed by +15.18%, over one month by -2.85%, over three months by +14.49% and over the past year by +269.11%.
Is Emergent Biosolutions a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Emergent Biosolutions (NYSE:EBS) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.36 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EBS as of January 2025 is 7.71. This means that EBS is currently overvalued and has a potential downside of -19.35%.
Probably not. Based on ValueRay Fundamental Analyses, Emergent Biosolutions (NYSE:EBS) is currently (January 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -26.36 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EBS as of January 2025 is 7.71. This means that EBS is currently overvalued and has a potential downside of -19.35%.
Is EBS a buy, sell or hold?
Emergent Biosolutions has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold EBS.
Emergent Biosolutions has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold EBS.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecast for EBS stock price target?
According to ValueRays Forecast Model, EBS Emergent Biosolutions will be worth about 8.3 in January 2026. The stock is currently trading at 9.56. This means that the stock has a potential downside of -12.87%.
According to ValueRays Forecast Model, EBS Emergent Biosolutions will be worth about 8.3 in January 2026. The stock is currently trading at 9.56. This means that the stock has a potential downside of -12.87%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 12 | 25.5% |
Analysts Target Price | 6 | -37.2% |
ValueRay Target Price | 8.3 | -12.9% |